Home・Elenco Azioni・Relay Therapeutics Inc

Relay Therapeutics Inc

Chiusa

SettoreSettore sanitario

19.73 -0.9

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.3

Massimo

19.95

Metriche Chiave
By Trading Economics
Entrata	-10M -84M
Vendite	-2.7M 350K
EPS	-0.41
Margine di Profitto	-23,916.286
Dipendenti	202
EBITDA	-10M -83M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+33.67% upside

Dividendi
By Acuity
Utili prossimi	5 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	277M 4.4B
Apertura precedente	20.63
Chiusura precedente	19.73

Notizie sul Sentiment di mercato

By Acuity

50%

163 / 340 Classifica in Healthcare

Relay Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

13 ago 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

10 ago 2026, 19:56 UTC

News

Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

7 ago 2026, 20:06 UTC

News

Correlated Moves

Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

6 ago 2026, 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 ago 2026, 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 ago 2026, 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 ago 2026, 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 lug 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 lug 2026, 17:36 UTC

Correlated Moves

News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

29 lug 2026, 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

28 lug 2026, 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

27 lug 2026, 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

22 lug 2026, 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

21 lug 2026, 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

20 lug 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Confronto tra pari

Modifica del prezzo

Relay Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

33.67% in crescita

Previsioni per 12 mesi

Media 26.64 USD 33.67%

Alto 31 USD

Basso 20 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Relay Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Relay Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

163 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.